U.S. markets open in 8 hours 7 minutes
  • S&P Futures

    3,813.50
    +19.50 (+0.51%)
     
  • Dow Futures

    30,445.00
    +135.00 (+0.45%)
     
  • Nasdaq Futures

    11,699.25
    +75.50 (+0.65%)
     
  • Russell 2000 Futures

    1,778.80
    +10.80 (+0.61%)
     
  • Crude Oil

    87.81
    +0.05 (+0.06%)
     
  • Gold

    1,730.20
    +9.40 (+0.55%)
     
  • Silver

    20.83
    +0.29 (+1.42%)
     
  • EUR/USD

    0.9920
    +0.0035 (+0.36%)
     
  • 10-Yr Bond

    3.7590
    0.0000 (0.00%)
     
  • Vix

    28.55
    -0.52 (-1.79%)
     
  • GBP/USD

    1.1355
    +0.0034 (+0.30%)
     
  • USD/JPY

    144.5550
    -0.0550 (-0.04%)
     
  • BTC-USD

    20,312.44
    +149.48 (+0.74%)
     
  • CMC Crypto 200

    461.61
    +3.21 (+0.70%)
     
  • FTSE 100

    7,052.62
    -33.84 (-0.48%)
     
  • Nikkei 225

    27,393.69
    +273.16 (+1.01%)
     

ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary Supplements

·1 min read

ChromaDex Corp (NASDAQ: CDXC) has announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs).

  • ChromaDex's proprietary healthy aging ingredient Niagen will be added to multi-ingredient Designs for Health formulas.

  • The Company says that Niagen is the world's first and only FDA-safety reviewed and patented form of nicotinamide riboside.

  • The new products will be available exclusively through the Company's extensive HCP network.

  • The Niagen inclusive formulas will be available to healthcare practitioners through the Designs for Health customers throughout the U.S., Canada, and Australia.

  • In October, ChromaDex announced findings from a clinical study of Niagen ingredient (nicotinamide riboside, NR) in patients with ataxia-telangiectasia (AT).

  • AT is a rare, inherited neurodegenerative disorder characterized by premature aging, cerebellar degeneration, immunodeficiency, and cancer predisposition.

  • The study found that supplementation with NR improved ataxia scores and increased immunoglobulins, or antibodies, in the immune-compromised patients under 18 years.

  • Price Action: CDXC shares are up 9.06% at $3.01 during the market session on the last check Thursday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.